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Abstract
Background: There is an urgent need to develop new innovative therapies for the control of advanced cancer. The 
combination of antigen-specific immunotherapy with the employment of immunomodulatory agents has emerged as 
a potentially plausible approach for the control of advanced cancer.
Methods: In the current study, we explored the combination of the DNA vaccine encoding calreticulin (CRT) linked to 
human papillomavirus type 16 (HPV-16) E7 antigen (CRT/E7) with the TLR7 agonist imiquimod for their ability to 
generate E7-specific immune responses and antitumor effects in tumor-bearing mice.
Results: We observed that treatment with CRT/E7 DNA in combination with imiquimod leads to an enhancement in 
the E7-specific CD8+ T cell immune responses and a decrease in the number of myeloid-derived suppressor cells in the 
tumor microenvironment of tumor-bearing mice. Furthermore, treatment with CRT/E7 DNA in combination with 
imiquimod leads to significantly improved antitumor effects and prolonged survival in treated mice. In addition, 
treatment with imiquimod led to increased number of NK1.1+ cells and F4/80+ cells in the tumor microenvironment. 
Macrophages and NK1.1+ cells were found to play an important role in the antitumor effects mediated by treatment 
with CRT/E7 DNA in combination with imiquimod.
Conclusions: Thus, our data suggests that the combination of therapeutic HPV DNA vaccination with topical 
treatment with the TLR7 agonist imiquimod enhances the antitumor immunity induced by DNA vaccination. The 
current study has significant implications for future clinical translation.
Background
Advanced stage cancers are difficult to control using con-
ventional therapies such as chemotherapy, surgery and
radiation. Therefore, new innovative therapies are
urgently required in order to combat the high mortality
and morbidity associated with cancers. Antigen-specific
immunotherapy has emerged as an attractive approach
for the treatment of cancers since it has the ability to spe-
cifically eradicate systemic tumors and control metasta-
ses without damaging normal cells. For example, in a
recent study, immunotherapy using synthetic long pep-
tide vaccine derived from human papillomavirus type 16
(HPV-16) E6 and E7 antigens has led to significant clini-
cal responses in patients with precancerous lesions of
gynecological malignancies [1].
DNA vaccination has become a potentially promising
approach for antigen-specific immunotherapy due to its
safety, stability and ease of preparation (for review, see
[2,3]). We have previously developed several innovative
strategies to enhance DNA vaccine potency by directly
targeting the DNA into the dendritic cells (DCs) in vivo
via gene gun as well as by modifying the properties of
antigen-expressing DCs (for review see [4,5]).
One of the strategies to enhance DNA vaccine potency
uses intracellular targeting strategies to enhance MHC
class I antigen presentation and processing in DCs. Previ-
ously, we have studied the linkage of calreticulin (CRT), a
Ca2+-binding protein located in the endoplasmic reticu-
lum (ER) (for review, see [6]) to several antigens, includ-
ing human papillomavirus type-16 (HPV-16) E7 [7,8], E6
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[9], and nucleocapsid protein of severe acute respiratory
syndrome coronavirus [10]. Intradermal administration
of DNA encoding CRT linked to any of these target anti-
gens led to a significant increase in the antigen-specific
CD8+ T cell immune responses and impressive antitu-
mor effects in vaccinated mice. Thus, CRT has been
shown to be highly potent in enhancing the antigen-spe-
cific immune responses and antitumor effects generated
by DNA vaccination in several preclinical models.
Another important innovative cancer therapy involves
the employment of immunomodulatory agents such as
imiquimod (for reviews see [11,12]). The exact mecha-
nism of action in which imiquimod and its analogs acti-
vate the immune system is still under active investigation.
Nevertheless, it is known that imiquimod activates
immune cells through the toll-like receptor 7 (TLR7),
commonly involved in pathogen recognition, on the cell
surface [13,14]. Cells activated by imiquimod via TLR-7
secrete cytokines such as IFN-α, IL-6 and TNF-α [15].
There is evidence that imiquimod, when applied to skin,
can lead to the activation of Langerhans cells, which sub-
sequently migrates to local lymph nodes to activate the
adaptive immune system [16]. Other cell types activated
by imiquimod include NK cells, macrophages and B-lym-
phocytes [16].
In the current study, we hypothesize that the combina-
tion of the DNA vaccine encoding CRT linked to HPV-16
E7 (CRT/E7) with topical application of imiquimod at the
site of the tumor will lead to increased infiltration of
effectior immune cells at the site of the tumor, resulting in
enhanced antitumor effects against E7-expressing tumors
in a preclinical model. We observed that treatment with
CRT/E7 DNA in combination with imiquimod leads to
decrease in the number of myeloid-derived suppressor
cells (MDSCs) but not T regulatory cells in the tumor
microenvironment of tumor-bearing mice. Treatment
with CRT/E7 DNA in combination with imiquimod was
also found to lead to an enhancement in the E7-specific
CD8+ T cell immune responses in tumor-bearing mice.
Furthermore, treatment with CRT/E7 DNA in combina-
tion with imiquimod leads to significantly improved anti-
tumor effects and prolonged survival in treated mice. In
addition, treatment with imiquimod led to increased
number of NK1.1+ cells and F4/80+ cells in the tumor
microenvironment. Furthermore, macrophages and
NK1.1+ cells were found to play an important role in the
antitumor effects mediated by treatment with CRT/E7
DNA in combination with imiquimod. The clinical impli-
cations of the current study are discussed.
Methods
Mice and cell line
Female C57BL/6 mice (H-2Kb and I-Ab), 5 to 6 wks of age,
were purchased from the National Cancer Institute. All of
the mice were maintained under specific pathogen-free
conditions in the animal facility at Johns Hopkins Hospi-
tal or Taipei Veterans General Hospital. Animals were
used in compliance with institutional animal health care
regulations, and all animal experimental procedures were
approved by the Johns Hopkins Institutional Animal Care
and Use Committee and Taipei Veterans General Hospi-
tal Experimental Animal Center.
The production and maintenance of TC-1 cells have
been described previously [17]. TC-1 cells were grown in
RPMI 1640, supplemented with 10% (v/v) fetal bovine
serum, 50 units/mL penicillin/streptomycin, 2 mmol/L L-
glutamine, 1 mmol/L sodium pyruvate, 2 mmol/L nones-
sential amino acids, and 0.4 mg/mL G418 at 37°C with 5%
CO2. The TC-1 cells have been tested and shown to be
free of mycoplasma and other contamination.
Plasmid DNA constructs
The generation of recombinant plasmid pcDNA3-CRT/
E7 has been described previously [7]. The accuracy of the
DNA construct was confirmed by DNA sequencing. For
the gene gun-mediated intradermal vaccination, 2 μg/
mouse of recombinant plasmid DNA were delivered to
the shaved abdominal region of C57BL/6 mice using a
helium-driven gene gun (Bio-Rad) with a previously
described protocol [18].
Flow cytometry analysis
For characterization of regulatory T cells and MDSC in
tumor microenvironment, C57BL/6 mice were divided
into four groups (5/group: untreated, imiquimod alone,
CRT/E7 alone, and combined group). All mice were inoc-
ulated with TC-1 cells (5 × 104/mouse) s.c. over right leg
at d0. For the untreated group, mice were regularly fol-
lowed after TC-1 implantation without specific treat-
ment. For the imiquimod group, each mouse received
topical imiquimod (50 mg/mouse) at the site of the tumor
every two days (begun at d6 for a total of 6 treatments).
For CRT/E7 alone group, each mouse was vaccinated
with pcDNA3-CRT/E7 2 μg via gene gun at d9, d13, and
d17. For the combined treatment group, each mouse
received the same treatment schedule as for each mono-
therapy alone group. Tumors were harvested at d24 for
flow cytometric analysis. Tumor cells were either stained
with PE-conjugated anti-CD4 (L3T4) and FITC-conju-
gated anti-CD25 (PC61) mAbs for quantification of regu-
latory T cells, or stained with stained with PE-conjugated
anti-CD11b (M1/70) and FITC-conjugated anti-Gr-1
(RB6-8C5) mAbs for quantification of MDSC.
For characterization of E7-specific CD8+  T cells in
tumor microenvironment, C57BL/6 mice were divided
into four groups (untreated, imiquimod alone, CRT/E7
alone, and combined group). All mice were inoculated
with TC-1 cells (5 × 104/mouse) s.c. over right leg at d0.Chuang et al. Journal of Biomedical Science 2010, 17:32
http://www.jbiomedsci.com/content/17/1/32
Page 3 of 9
For the untreated group, mice were regularly followed
after TC-1 implantation without specific treatment. For
the imiquimod group, each mouse received topical imi-
quimod (50 mg/mouse) at the site of the tumor every two
days (begun at d6 for a total of 6 treatments). For CRT/E7
alone group, each mouse was vaccinated with pcDNA3-
CRT/E7 2 μg via gene gun at d9, d13, and d17. For the
combined treatment group, each mouse received the
same treatment schedule as for each monotherapy alone
group. Tumors were harvested at d24 for immune
response analysis. Before intracellular cytokine staining,
pooled tumors from each treatment group were sepa-
rately incubated for 16 h with the H2-Db-restricted CTL
epitope (aa 49-57) (1.0 μmol/L). Cells were then har-
vested and stained for CD8 and IFN-γ using previously
described standard protocols [19]. Samples were ana-
lyzed on a FACSCalibur flow cytometer using CellQuest
software. All of the analyses shown were carried out on a
gated lymphocyte population.
As for evaluation of change of various immune effec-
tors in tumor microenvironment after imiquimod and
CRT/E7 treatment, mice were divided into two groups (5/
group: vehicle treated or imiquimod treated), and were
implanted with TC-1 (5 × 104/mouse) at d0. Each mouse
received topical vehicle cream or imiquimod (50 mg/
mouse) every two days initiated at d6 for a total of 6
times. Tumors were harvested 6 hours after last treat-
ment. Tumor cells were then made into single cell sus-
pension, washed once in FACScan buffer, and stained
with surface markers for various innate and adaptive
effectors including PE-conjugated anti-CD4 (L3T4), PE-
conjugated anti-CD8 (53-6.7), FITC-conjugated anti-GR-
1 (RB6-8C5), PE-conjugated anti-CD19 (1D3), PE-conju-
gated anti-NK1.1 (PK136), and PE-Cy5-conjugated anti-
F4/80 (BM8). Cells were subjected to flow cytometry
analysis gated on lymphocyte population.
In vivo evaluation of the antitumor effects generated by 
combined treatment
In order to evaluate monotherapy alone or combined
treatment for the inhibition of TC-1 tumor growth, we
designed a two-step experiment. For the first-step experi-
ment, we evaluated the anti-tumor effects of imiquimod
alone therapy. Mice were divided into 2 groups (4/group,
untreated or imiquimod treated), which were implanted
with TC-1 (5 × 104/mouse) subcutaneously at d0. Mice
were then left untreated or treated with imiquimod (50
mg/mouse) at the site of the tumor every two days initi-
ated at d6 for a total of 6 treatments. Mice were eutha-
nized at d21 and tumors were harvested and
photographed for tumor size comparison. After having
proved that imiquimod was effective as a single agent, we
proceeded with the second-step experiment. Mice were
divided into four groups (5/group: untreated, imiquimod
alone, CRT/E7 alone, and combined group). All mice
were inoculated with TC-1 cells (5 × 104/mouse) s.c. over
right leg at d0. For the untreated group, mice were regu-
larly followed for tumor growth after TC-1 implantation
without specific treatment. For the imiquimod group,
each mouse received topical imiquimod (50 mg/mouse)
at the site of the tumor every two days (began at d6 for a
total of 6 treatments). For CRT/E7 alone group, each
mouse was vaccinated with pcDNA3-CRT/E7 2 μg via
gene gun at d9, d13, and d17. For the combined treatment
group, each mouse received the same treatment schedule
as for each monotherapy alone group. Tumor sizes in the
mice were monitored and measured every 3-4 days using
digital calipers.
In vivo antibody depletion experiments
In order to identify the subset of lymphocytes that were
important for anti-tumor effects of combined treatments
of imiquimod and pcDNA3-CRT/E7 DNA vaccine, mice
were divided into 4 groups (combined treatments without
depletion, combined treatments with depletion of neu-
trophils, combined treatments with depletion of NK1.1+
cells, and combined treatments with depletion of mac-
rophages) using methods similar to what we have
described previously [17]. All mice were implanted with
TC-1 (5 × 104/mouse) at d0, and were then treated with
imiquimod (at d2, d4, d6, d8, d10, and d12) and pcDNA-
CRT/E7 2 μg (d5 and d12). Mice were either undepleted
or depleted of macrophages (using clodronate lipo-
somes), NK1.1+ cells (using anti-mouse NK1.1 mAbs,
PK136), or neutrophils (using anti-mouse Gr-1 mAbs,
RB6-8C5), one day before and 3 days after TC-1 implan-
tation and thereafter once per week until the end of fol-
low-up.
Statistical analysis
All data expressed as mean ± standard deviation (S.D.)
are representative of at least two different experiments.
Comparisons between individual data points for tumor
sizes were made using a Student's t-test or repeated mea-
sure ANOVA (analysis of variance) test. Differences in
s u r v i v a l  b e t w e e n  e x p e r i m e n t a l  g r o u p s  w e r e  a n a l y z e d
using the log-rank test. Tumor sizes were calculated using
the following equation: (tumor length×width×height)/2.
Death of mouse was arbitrarily defined as tumor diame-
ter greater than 2 cm.
Results
Treatment with CRT/E7 DNA in combination with 
imiquimod leads to decrease in the number of myeloid-
derived suppressor cells but not CD4+CD25+ T cells in the 
tumor microenvironment of tumor-bearing mice
In order to determine the number of CD4+CD25+ T cells
(which are mainly comprised of T regulatory cells) and
myeloid-derived suppressor cells in the tumor microenvi-
ronment of tumor-bearing mice treated with CRT/E7Chuang et al. Journal of Biomedical Science 2010, 17:32
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DNA with imiquimod, we inoculated C57BL/6 mice with
TC-1 cells on d0 and treated them with or without topical
imiquimod (50 mg/mouse) every two days starting from
d6 for a total of 6 treatments). Mice were then vaccinated
with CRT/E7 DNA via gene gun on d9, d13, and d17.
Untreated mice were used as controls. Tumors were har-
vested on d24 and characterized for the presence of T
regulatory cells and myeloid-derived suppressor cells by
flow cytometry analysis. As shown in Figure 1, mice
treated with CRT/E7 DNA in combination with imiqui-
mod demonstrated significantly lower numbers of myel-
oid-derived suppressor cells compared to the other
treated mice. In comparison, there was no significant dif-
ference in the number of CD4+CD25+ T cells in mice
treated with CRT/E7 DNA in combination with imiqui-
mod compared to any of the other groups. Thus, our data
indicate that treatment with imiquimod in combination
with DNA vaccination can reduce the number of myel-
oid-derived suppressor cells in the tumor microenviron-
ment of treated mice.
Treatment with CRT/E7 DNA in combination with 
imiquimod leads to an enhancement in the E7-specific 
CD8+ T cell immune responses in tumor-bearing mice
In order to determine the E7-specific immune responses
in tumor-bearing mice vaccinated with CRT/E7 DNA
with imiquimod, we inoculated C57BL/6 mice with TC-1
cells on d0 and treated them with CRT/E7 DNA vaccine
and/or imiquimod as described in Figure 1. Splenocytes
from tumor-bearing mice were harvested at d24 and
characterized for the E7-specific CD8+ T cell immune
responses by intracellular cytokine staining followed by
Figure 1 Characterization of the T regulatory cells and myeloid-derived suppressor cells (MDSC) in the tumor microenvironment following 
vaccination with CRT/E7 DNA with or without imiquimod in tumor-bearing mice. C57BL/6 mice were divided into four groups (5/group: un-
treated, imiquimod alone, CRT/E7 alone, and combined group). All mice were inoculated with TC-1 cells (5 × 104/mouse) s.c. over right leg at d0. For 
the untreated group, mice were regularly followed after TC-1 implantation without specific treatment. For the imiquimod group, each mouse received 
topical imiquimod (50 mg/mouse) every two days (began at d6 for a total of 6 treatments). For CRT/E7 alone group, each mouse was vaccinated with 
2 μg of pcDNA3-CRT/E7 DNA via gene gun at d9, d13, and d17. For the combined treatment group, each mouse received the same treatment sched-
ule as for each monotherapy alone group. Tumors were harvested at d24 for flow cytometric analysis. Tumor cells were either stained with PE-conju-
gated anti-CD4 (L3T4) and FITC-conjugated anti-CD25 (PC61) mAbs (A & B) or with PE-conjugated anti-CD11b (M1/70) and FITC-conjugated anti-Gr-
1 (RB6-8C5) mAbs (C & D). Plots were gated on lymphocyte population. A) Representative flow cytometry data demonstrating the percentage of 
CD4+CD25+ cells. B) Bar graph representing the percentage of Tregs among the tumor-infiltrating lymphocytes. C) Representative flow cytometry 
data demonstrating the percentage of CD11b+Gr-1+ cells. D) Bar graph representing the percentage of Tregs among the tumor-infiltrating lympho-
cytes. C denotes untreated group, and I denotes imiquimod treated group. Representative data from one of three independent experiments are 
shown. *, P < 0.05; **, P < 0.01.Chuang et al. Journal of Biomedical Science 2010, 17:32
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flow cytometry analysis. As shown in Figure 2, mice
treated with CRT/E7 DNA in combination with topical
application of imiquimod demonstrated significantly
higher numbers of E7-specific CD8+ T cells compared to
mice treated with CRT/E7 alone. Thus, our data indicate
that treatment with imiquimod in combination with
DNA vaccination can significantly enhance the E7-spe-
cific CD8+ T cell immune responses in treated mice.
Treatment with CRT/E7 DNA in combination with 
imiquimod leads to significantly improved antitumor 
effects and prolonged survival in treated mice
In order to determine the therapeutic antitumor effects
generated in tumor-bearing mice vaccinated with CRT/
E7 DNA with imiquimod, we inoculated C57BL/6 mice
with TC-1 cells on d0 and treated them with CRT/E7
DNA vaccine and/or topical application of imiquimod as
described in Figure 1. Tumor growth was monitored over
time. As shown in Figure 3A, mice treated with CRT/E7
DNA in combination with imiquimod demonstrated sig-
nificantly lower tumor size over time compared to mice
treated with CRT/E7 alone. Furthermore, mice treated
with CRT/E7 alone or imiquimod alone demonstrated
significantly lower tumor volumes compared to the mice
without treatment (control). In addition, mice treated
with CRT/E7 DNA in combination with topical applica-
tion of imiquimod demonstrated significantly prolonged
s u rvi va l  c o m p a r ed  t o  m i c e  t r ea t ed  wi t h  CR T / E 7  a l o n e
(Figure 3B). Thus, our data indicate that topical treatment
with imiquimod in combination with therapeutic HPV
DNA vaccination can enhance the therapeutic antitumor
effects against TC-1 tumors in treated mice.
Figure 2 Characterization of the E7-specific CD8+ T cell immune responses following vaccination with CRT/E7 DNA with or without imiqui-
mod in tumor-bearing mice. C57BL/6 mice were divided into four groups (5/group: untreated, imiquimod alone, CRT/E7 alone, and combined 
group). All mice were inoculated with TC-1 cells (1 × 104/mouse) s.c. over right leg at d0. Treatment schedules were the same as in Figure 1. Spleno-
cytes from tumor-bearing mice were harvested at d24 for immune response analysis, stimulated with E7 epitope (aa49-57), and stained for both CD8 
and intracellular interferon-γ (IFN-γ). A) Representative flow cytometry data demonstrating the percentage of CD8+IFN-γ+ T cells. The numbers of CD8+ 
IFN-γ+ double positive T cells are indicated in the upper right hand corner of each representative dot plot. B) Bar graph representing the number of 
E7-specific CD8+ T cells/3 × 105 splenocytes (*, p < 0.05). Representative data from one of three independent experiments are shown.Chuang et al. Journal of Biomedical Science 2010, 17:32
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Treatment with imiquimod leads to increased number of 
NK1.1+ cells and F4/80+ cells in the tumor 
microenvironment
In order to determine the key immune cells in the tumor
microenvironment that were upregulated following imi-
quimod treatment, C57BL/6 mice were implanted with
TC-1 (5 × 104/mouse) at d0 and divided into two groups
(5/group: vehicle treated or imiquimod treated). Each
mouse received topical vehicle cream or imiquimod every
two days initiated at d6 for a total of 6 times. T umors
were harvested 6 hours after last imiquimod treatment.
Tumor cells were then made into single cell suspension
and analyzed for the presence of various immune cell
markers by flow cytometry analysis. As shown in Figure
4, mice treated with topical application of imiquimod
demonstrated significantly higher number of NK1.1+
cells, which includes both NK cells as well as NKT cells,
and F4/80+ inflammatory cells in the tumor microenvi-
ronment compared to mice treated with the vehicle.
Thus, our data indicate that imiquimod treatment leads
to the upregulation of NK1.1+ cells and F4/80+ inflam-
matory cells in the tumor microenvironment.
Macrophages and NK1.1+ cells play an important role in 
the antitumor effects mediated by treatment with CRT/E7 
DNA in combination with imiquimod
In order to determine the immune cells that play an
important role in the antitumor effects mediated by CRT/
E7 DNA vaccination followed by imiquimod treatment,
we performed an in vivo depletion experiment. C57BL/6
mice were divided into 4 groups (5/group). All mice were
implanted subcutaneously with TC-1 at d0, and were
then treated with imiquimod and CRT/E7 DNA vaccine
as described. Mice were either depleted of macrophages
(using clodronate liposomes), NK1.1+ cells (using anti-
mouse NK 1.1 mAbs, PK136), or neutrophils (using anti-
mouse Gr-1 mAbs, RB6-8C5), one day before and 3 days
after TC-1 implantation and thereafter once per week
until the end of follow-up. Undepleted mice were used as
controls. As shown in Figure 5, treated mice depleted of
macrophages or NK1.1+ cells demonstrated significant
increase in tumor growth compared to undepleted mice
or mice depleted of neutrophils. Thus, our data indicate
that macrophages and NK1.1+ cells play an important
role in the antitumor effects mediated by treatment with
CRT/E7 DNA in combination with imiquimod.
Discussion
In the current study, we observed that treatment with
CRT/E7 DNA in combination with imiquimod leads to
decrease in the number of myeloid-derived suppressor
cells but not CD4+CD25+ T cells in the tumor microen-
vironment of tumor-bearing mice. Treatment with CRT/
E7 DNA in combination with imiquimod was also found
to lead to an enhancement in the E7-specific CD8+ T cell
immune responses and improved antitumor effects and
prolonged survival in treated mice. Macrophages and
Figure 3 Characterization of the therapeutic antitumor effects generated by treatment with E7-CRT in combination with imiquimod in tu-
mor-bearing mice. C57BL/6 mice (5/group: untreated, imiquimod alone, CRT/E7 alone, and combined group) were implanted with TC-1 (5 × 104/
mouse) at d0. Treatment schedules were the same as described in Figure 1. Tumor growth was monitored over time. A) Line graph depicting the 
tumor sizes in tumor-bearing mice treated with the different regimens. (*, p < .05) B) Kaplan-Meier survival curve of the mice treated with the various 
regimens (*, p < 0.05, compared between CRT/E7 alone and the combined group). Representative data from one of three independent experiments 
are shown.Chuang et al. Journal of Biomedical Science 2010, 17:32
http://www.jbiomedsci.com/content/17/1/32
Page 7 of 9
NK1.1+ cells were found to play an important role in the
antitumor effects mediated by treatment with CRT/E7
DNA in combination with imiquimod. Our data is quite
consistent with the recent clinical trials using therapeutic
HPV vaccines in conjunction with imiquimod in patients
with vulvar intraepithelial neoplasia. In that study, treat-
ment with imiquimod and vaccination led to clinical
responses in some of the patients, with a significant
increase local infiltration of CD8+ and CD4+ T cells in
the lesions of these patients [20].
In our study, we have observed that depletion of mac-
rophages in TC-1 tumor-bearing mice treated with imi-
quimod and CRT/E7 DNA vaccines led to the loss of
antitumor effect, suggesting the importance of mac-
rophages in the antitumor effect generated by imiquimod
in combination with the DNA vaccine (Figure 5). Tumor-
bearing mice treated with imiquimod also showed a sig-
nificant increase in the number of F4/80+ macrophages
in the tumor microenvironment (Figure 4). Taken
together, these data suggest that the combination of CRT/
E7 DNA vaccination with imiquimod treatment may
result in an increase in M1 macrophages in the tumor,
which can contribute to the antitumor effect (for reviews
see [21,22]) It has been shown that TC-1 tumors contain
significant number of M2 macrophages, that lead to sup-
pression of antitumor T-cell response, thus facilitating
tumor growth [23]. Thus, treatment of TC-1 tumors with
imiquimod and the CRT/E7 DNA vaccine may result in a
Figure 4 Characterization of the levels of various immune cells in the tumor microenvironment following treatment with imiquimod. 
C57BL/6 mice were divided into two groups (5/group: vehicle treated or imiquimod treated) and were implanted with TC-1 (5 × 104/mouse) at d0. 
Each mouse received topical vehicle cream or imiquimod (50 mg/mouse) every two days initiated at d6 for a total of 6 times. Tumors were harvested 
6 hours after last imiquimod treatment. Tumor cells were then made into single cell suspension, washed once in FACScan buffer, and stained with 
surface markers for various innate and adaptive effectors including PE-conjugated anti-CD4 (L3T4), PE-conjugated anti-CD8 (53-6.7), FITC-conjugated 
anti-GR-1 (RB6-8C5), PE-conjugated anti-CD19 (1D3), PE-conjugated anti-NK1.1 (PK136), and PE-Cy5-conjugated anti-F4/80 (BM8). Cells were subject-
ed to flow cytometric analysis gated on lymphocyte population (*, p < 0.05, imiquimod versus vehicle). Representative data from one of three inde-
pendent experiments are shown.Chuang et al. Journal of Biomedical Science 2010, 17:32
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switch from immunosuppressive M2 macrophage pheno-
type to the inflammatory M1 phenotype.
We showed that treatment with imiquimod leads to
increased number of NK1.1+ cells and F4/80+ cells in the
tumor microenvironment (Figure 4). Furthermore, our
antibody depletion experiments indicated that NK1.1+
cells are essential for the observed antitumor effects (Fig-
ure 5). NK cells have been shown to express TLR7 and
imiquimod-mediated activation of NK cells through
TLR7 may result in IFN-γ production [24]. Thus, it is
likely that not only can NK cells directly lead to cytotoxic
effects, but NK cells can also lead to increased expression
of IFN-γ which may lead to upregulation of MHC class I,
which may render tumor cells more susceptible to killing
by CD8+ T cells.
We observed that treatment with CRT/E7 DNA in
combination with imiquimod leads to a reduction in the
number of myeloid-derived suppressor cells (MDSCs) in
the tumor microenvironment of tumor-bearing mice
(Figure 1). It has been shown that myeloid-derived sup-
pressor cells play an important immunosuppressive role
in the tumor microenvironment (for reviews, see [25-
27]). The reduction in MDSCs may potentially lead to
improved antigen-specific CD8+ T cell immune
responses, resulting in better tumor killing.
The employment of imiquimod for tumor treatment
has significant potential for clinical translation. Currently
there is one ongoing phase I trial to assess the immunoge-
nicity, safety, tolerability and efficacy of pNGVL4a-Sig/
E7(detox)/HSP70 DNA vaccine [28] followed by a
booster vaccination with a recombinant vaccinia express-
ing HPV-16/18 E6 and E7 (TA-HPV) [29] in combination
with locally applied TLR7 agonist, imiquimod in patients
with HPV-16+ high grade cervical intraepithelial neopla-
sia (CIN3) http://www.clinicaltrial.gov/ct2/show/
NCT00788164. The application of imiquimod may gener-
ate local inflammation in the local lesional microenviron-
ment, thus allowing the localized immune effector cells to
access lesional epithelium in patients with CIN lesions,
and function in tumor destruction in the local microenvi-
ronment.
In summary, our study demonstrates that the combina-
tion of therapeutic HPV DNA vaccination with topical
treatment with the TLR7 agonist, imiquimod enhances
the antitumor immunity induced by DNA vaccination.
Our study serves as an important foundation for future
clinical translation.
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Figure 5 In vivo depletion experiment. C57BL/6 mice were divided 
into 4 groups (5/group). All mice were implanted with TC-1 (5 × 104/
mouse) at d0, and were then treated with imiquimod (at d2, d4, d6, d8, 
d10, and d12) and pcDNA-CRT/E7 2 μg (d5 and d12). Mice were either 
depleted of macrophages (using clodronate liposomes), NK1.1+ cells 
(using anti-mouse NK 1.1 mAbs, PK136), or neutrophils (using anti-
mouse Gr-1 mAbs, RB6-8C5), one day before and 3 days after TC-1 im-
plantation and thereafter once per week until the end of follow-up. 
Undepleted mice were used as controls. Line graph depicting the tu-
mor sizes in tumor-bearing mice treated with the different regimens. 
Representative data from one of three independent experiments are 
shown.Chuang et al. Journal of Biomedical Science 2010, 17:32
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